Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).

Emmanuel S. Antonarakis,José Manuel Rodríguez,Marine Gross-Goupil,Jeffrey C. Goh,Ulka N. Vaishampayan,Ronald de Wit,Tuomo Alanko,Satoshi Fukasawa,Ken-ichi Tabata,Susan Feyerabend,Raanan Berger,Haiyan Wu,Jeri Kim,Charles Schloss,Ping Qiu,Leah Suttner,Razvan Cristescu,Matthew J. Marton,Johann S. de Bono

Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).

2020

Emmanuel S. Antonarakis
José Manuel Rodríguez
Marine Gross-Goupil
Jeffrey C. Goh
Ulka N. Vaishampayan
Ronald de Wit
Tuomo Alanko
Satoshi Fukasawa
Ken-ichi Tabata
Susan Feyerabend
Raanan Berger
Haiyan Wu
Jeri Kim
Charles Schloss
Ping Qiu
Leah Suttner
Razvan Cristescu
Matthew J. Marton
Johann S. de Bono

5526Background: In the phase II KEYNOTE-199 study (NCT02787005), pembrolizumab monotherapy demonstrated antitumor activity in pts with docetaxel-refractory mCRPC (n = 258). Here we evaluated the as...

Keywords:

Oncology
Internal medicine
Pembrolizumab
Prostate cancer
Refractory
castration resistant
in patient
Biomarker Analysis
Pathology
Docetaxel
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations